Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry

Table 6 Summary of multivariate logistic regression models for hospital mortality

Model Number	Hospital Mortality Adjusted for	N Used/Read in Model*	R-Square	Goodness of Fit Chi-Square^†	LDC Effect Chi-Square	Odds Ratio Point Estimate (95% CI)
1	Propensity Quintiles¹	6,833/ 8,968	0.131	0.874	<0.0001	1.398 (1.256, 1.556)
2	Age, 7 OD	7,289/ 8,968	0.187	0.202	<0.0001	1.382 (1.244, 1.536)
3	Age, Propensity Quintiles, 7 OD (CORE MODEL)	6,833/8,968	0.186	0.296	<0.0001	1.392 (1.247, 1.553)
4	CORE MODEL, including Vasopressor-yes data only	5,403/7,160	0.158	0.814	<0.0001	1.328 (1.180, 1.494)
5	CORE MODEL, including Vasopressor-no data only	1,430/1,808	0.124	0.260	0.5456	1.115 (0.784, 1.585)
6	CORE MODEL, excluding DAA use	6,330/8,345	0.194	0.511	<0.0001	1.470 (1.310, 1.650)
7	CORE MODEL, including HDC use	7,519/10,925	0.184	0.619	<0.0001	1.369 (1.235, 1.517)
8	CORE MODEL, Source of Infection, Active Cancer, APACHE II Scores², Surgical Status, Vasopressors	4,995/8,968	0.264	0.154	0.0001	1.301 (1.138, 1.487)
9	Age, Propensity Quintiles, Source of Infection, Active Cancer, APACHE II Scores², Number of organ dysfunctions, including vasopressor-yes only data	3,955/7,160	0.201	0.5503	<0.0001	1.349 (1.173, 1.551)
10	Age, Propensity Quintiles, Source of Infection, Active Cancer, APACHE II Scores², Number of Organ Dysfunctions, including vasopressor-no data only	1,040/1,808	0.218	0.670	0.4335	1.194 (0.766, 1.860)
11	Logistic regression with the 12 variables used in the Propensity Score Model and Country³	6,833/8,968	0.197	0.082	<0.0001	1.414 (1.252, 1.598)

* Includes only patients with severe sepsis and complete vasopressor and low-dose corticosteroid use. Excludes patients with high-dose and chronic corticosteroid use.
^† P-value from the Hosmer and Lemeshow Goodness-of-Fit Test.
¹ Propensity Quintiles based on age, 7 OD (cardiovascular, respiratory, renal, hematology, hepatic, metabolic, neurological), Surgical Status, Chronic Lung Disease Status, Active Cancer Status, and other Chronic Disabling Condition.
² APACHE II Scores in models were not imputed to the mean.
³ Countries included: Belgium, Germany, Poland, Europe Others, Argentina, Brazil, Chile, Colombia, Latin America Others, Mexico, Peru, Australia, Oceania Others, Asia Others, India, Israel, Malaysia, Philippines, Taiwan, and Thailand.
LDC, Low-Dose Corticosteroids; CI, Confidence Intervals; OD, Organ Dysfunction; DAA, Drotrecogin Alfa (Activated); HDC, High-Dose Corticosteroids; APACHE, Acute Physiology and Chronic Health Evaluation.

ISSN: 1364-8535